Welcome to our dedicated page for Rapt Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on Rapt Therapeutics stock.
RAPT Therapeutics, Inc. (Nasdaq: RAPT) is a clinical-stage immunology-based biopharmaceutical company, and its news flow reflects the progress and risks of drug development in inflammatory and immunological diseases. Company announcements routinely describe advances in its pipeline, particularly its anti-IgE monoclonal antibody program ozureprubart (formerly RPT904), as well as financial updates and investor outreach activities.
Visitors to this news page can review press releases on key clinical milestones, such as FDA clearance of an Investigational New Drug application, initiation of the prestIgE Phase 2b trial of ozureprubart in IgE-mediated food allergy, and positive topline data from a Phase 2 trial in chronic spontaneous urticaria conducted by partner Shanghai Jeyou Pharmaceutical Co., Ltd. RAPT’s news also highlights how these data compare to existing therapies like omalizumab in terms of dosing intervals and measured endpoints within the reported studies.
RAPT frequently reports quarterly financial results, detailing research and development and general and administrative expenses, net losses and cash, cash equivalents and marketable securities. News items also cover capital-raising events, such as the pricing and completion of underwritten public offerings of common stock, and the company’s estimates regarding how long its capital resources may fund operations based on current plans.
In addition, RAPT issues press releases about participation in healthcare and investor conferences, including major events hosted by firms such as J.P. Morgan, Wells Fargo, Guggenheim, Stifel, TD Cowen, Cantor and H.C. Wainwright. These updates indicate when management will present company overviews or fireside chats and how investors can access related webcasts or archived presentations.
For investors and observers following RAPT, this news feed provides a consolidated view of clinical trial developments, regulatory interactions, financial disclosures and corporate events that shape the company’s progress in developing therapies for inflammatory and immunological diseases.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO Brian Wong will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 3:00 pm Eastern Time. The event aims to discuss the company’s advancements in developing oral small molecule therapies for oncology and inflammatory diseases. Interested parties can access the live webcast and archived recording on the RAPT Therapeutics website. The company is focused on developing selective small molecules targeting critical immune drivers, including drug candidates FLX475 and RPT193.
RAPT Therapeutics reported a net loss of $16.5 million for Q1 2021, up from $13.1 million in Q1 2020. Research and development expenses rose to $13.8 million due to increased clinical trial costs and personnel expenses. General and administrative expenses increased to $4.0 million, impacted by higher stock-based compensation and insurance costs. The company is progressing in its oncology and inflammation programs, highlighting recent preclinical data and the completion of enrollment in a Phase 1b trial for RPT193. Cash and equivalents stood at $98.4 million as of March 31, 2021.
RAPT Therapeutics has completed enrollment in its Phase 1b clinical trial of RPT193 for moderate to severe atopic dermatitis, with results expected by mid-2021. The trial aims to establish safety and clinical efficacy through multiple endpoints, including the Eczema Area and Severity Index and pruritis scale. An encouraging outcome may position RPT193 as a viable oral treatment option against existing injectable therapies, targeting significant unmet needs in inflammatory diseases.
RAPT Therapeutics (Nasdaq: RAPT) announced its financial results for Q4 and the year ending December 31, 2020. The company reported a net loss of $12.7 million for Q4 2020, slightly better than the $13.2 million loss in Q4 2019. Annual net loss increased to $52.9 million from $43 million in 2019. Research and development expenses rose to $45.5 million in 2020, driven by clinical trial costs for FLX475 and RPT193. As of December 31, 2020, cash and equivalents totaled $111.5 million. Key clinical advancements were noted for both lead programs, with upcoming data readouts expected in 2021.
RAPT Therapeutics (RAPT) reported promising data from preclinical studies to be presented at the American Association for Cancer Research annual meeting. Key findings include the ability of CCR4 antagonists to enhance CAR T-cell therapy's efficacy in solid tumors, with a significant increase in survival rates in murine models. Additionally, small-molecule HPK1 inhibitors demonstrated enhanced T-cell responses, while GCN2 inhibitors showed potential to restore immunity in the tumor microenvironment. These developments highlight RAPT's ongoing commitment to advancing immunology-based therapies for cancer treatment.
SOUTH SAN FRANCISCO, Calif., March 3, 2021 - RAPT Therapeutics (Nasdaq: RAPT) announced CEO Brian Wong will speak at two investor conferences this month. The H.C. Wainwright Global Life Sciences Conference features a company presentation available on March 9 at 7:00 am ET. Wong will also participate in the 33rd Annual Roth Conference on March 15 at 2:00 pm ET, discussing novel immuno-oncology targets. RAPT specializes in oral small molecule therapies for oncology and inflammatory diseases, focusing on advanced drug candidates like FLX475 and RPT193.
RAPT Therapeutics announced that its CEO, Brian Wong, M.D., Ph.D., will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 12:00 PM ET. The company focuses on immunology-based therapies for oncology and inflammatory diseases.
RAPT is developing small molecule therapies, including FLX475 and RPT193, targeting C-C motif chemokine receptor 4 (CCR4). For more details, visit the company's website.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Brian Wong, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 3:40 PM Eastern Time. The company focuses on developing oral small molecule therapies for oncology and inflammatory diseases. RAPT has advanced drug candidates targeting C-C motif chemokine receptor 4 (CCR4) and is exploring additional targets in early development. For those interested, the presentation will be available live and archived on their website.
RAPT Therapeutics announced that its executives will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Nov. 23, 2020, at 10:00 a.m. ET. The chat will feature Brian Wong, M.D., Ph.D., President and CEO, and Rodney Young, CFO. A replay of the discussion will be available on RAPT’s website. The company focuses on developing oral small molecule therapies for oncology and inflammatory diseases, with notable drug candidates including FLX475 and RPT193, targeting critical immune mechanisms.
RAPT Therapeutics reported a net loss of $14.6 million for Q3 2020, an increase from $10 million in Q3 2019. Research and development expenses rose to $12.9 million due to higher costs for clinical trials of FLX475 and RPT193. In the first nine months of 2020, the net loss totaled $40.2 million, up from $29.8 million in 2019. The company is advancing clinical trials and expects initial data from FLX475 and RPT193 by mid-2021. Cash and cash equivalents stood at $122.8 million as of September 30, 2020.